A recent Swiss multicenter retrospective study of EGFR-mutant NSCLC patients treated with first-line osimertinib found that 77% of patients experienced oligoprogressive disease, with the lung (62%) and brain (30%) being the most common progression sites. Here, EGFR is linked to non-small cell lung carcinoma.